Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 224 entries
Sorted by: Best Match Show Resources per page
Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs.

Water research

Tan C, Zhao H, Wang X, Yu H, Chong S, Xu Y, Du E, Chen M, Peng X, Su L.
PMID: 34952455
Water Res. 2021 Dec 19;210:117981. doi: 10.1016/j.watres.2021.117981. Epub 2021 Dec 19.

As a natural source of visible light and a type of renewable energy, solar energy is extensively used in the field of photochemistry. In this study, solar was employed to activate persulfate (PS) to degrade typical micropollutants. The removal...

Cite
Tan C, Zhao H, Wang X, et al. Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs. Water Res. 2021;210:117981doi: 10.1016/j.watres.2021.117981.
Tan, C., Zhao, H., Wang, X., Yu, H., Chong, S., Xu, Y., Du, E., Chen, M., Peng, X., & Su, L. (2021). Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs. Water research, 210117981. https://doi.org/10.1016/j.watres.2021.117981
Tan, Chaoqun, et al. "Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs." Water research vol. 210 (2021): 117981. doi: https://doi.org/10.1016/j.watres.2021.117981
Tan C, Zhao H, Wang X, Yu H, Chong S, Xu Y, Du E, Chen M, Peng X, Su L. Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs. Water Res. 2021 Dec 19;210:117981. doi: 10.1016/j.watres.2021.117981. Epub 2021 Dec 19. PMID: 34952455.
Copy Download .nbib Format: NLM
Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.

Molecular immunology

Cardoso JMO, Brito RCF, Mathias FAS, Reis LES, Vieira JFP, Ostolin TLVDP, Andrade HM, Ramos GS, Frézard F, Aguiar-Soares RDO, Roatt BM, Reis AB.
PMID: 34814056
Mol Immunol. 2021 Nov 20;141:70-78. doi: 10.1016/j.molimm.2021.11.011. Epub 2021 Nov 20.

This study compared the therapeutic potential of the chemotherapy using meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes (Nano Sb

Cite
Cardoso JMO, Brito RCF, Mathias FAS, et al. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Mol Immunol. 2021;141:70-78doi: 10.1016/j.molimm.2021.11.011.
Cardoso, J. M. O., Brito, R. C. F., Mathias, F. A. S., Reis, L. E. S., Vieira, J. F. P., Ostolin, T. L. V. D. P., Andrade, H. M., Ramos, G. S., Frézard, F., Aguiar-Soares, R. D. O., Roatt, B. M., & Reis, A. B. (2021). Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Molecular immunology, 14170-78. https://doi.org/10.1016/j.molimm.2021.11.011
Cardoso, Jamille Mirelle de Oliveira, et al. "Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis." Molecular immunology vol. 141 (2021): 70-78. doi: https://doi.org/10.1016/j.molimm.2021.11.011
Cardoso JMO, Brito RCF, Mathias FAS, Reis LES, Vieira JFP, Ostolin TLVDP, Andrade HM, Ramos GS, Frézard F, Aguiar-Soares RDO, Roatt BM, Reis AB. Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. Mol Immunol. 2021 Nov 20;141:70-78. doi: 10.1016/j.molimm.2021.11.011. Epub 2021 Nov 20. PMID: 34814056.
Copy Download .nbib Format: NLM
Tongue Nodule as Primary Manifestation of American Cutaneous Leishmaniasis in an Immunocompetent Patient.

Head and neck pathology

Botelho MCB, Ferreira LL, Fikaris S, Prado-Ribeiro AC, Soubhia AMP, Biasoli ER, Miyahara GI, Bernabé DG.
PMID: 33372239
Head Neck Pathol. 2021 Sep;15(3):1069-1073. doi: 10.1007/s12105-020-01253-w. Epub 2020 Dec 28.

Leishmaniasis is a parasitic disease considered an endemic public health problem in developing countries, where it is a reportable disease. Isolated oral manifestation is rare, and its clinical manifestations are variable. In this paper we describe an unusual case...

Cite
Botelho MCB, Ferreira LL, Fikaris S, et al. Tongue Nodule as Primary Manifestation of American Cutaneous Leishmaniasis in an Immunocompetent Patient. Head Neck Pathol. 2020;15(3):1069-1073doi: 10.1007/s12105-020-01253-w.
Botelho, M. C. B., Ferreira, L. L., Fikaris, S., Prado-Ribeiro, A. C., Soubhia, A. M. P., Biasoli, E. R., Miyahara, G. I., & Bernabé, D. G. (2021). Tongue Nodule as Primary Manifestation of American Cutaneous Leishmaniasis in an Immunocompetent Patient. Head and neck pathology, 15(3), 1069-1073. https://doi.org/10.1007/s12105-020-01253-w
Botelho, Maria Clara Bertolini, et al. "Tongue Nodule as Primary Manifestation of American Cutaneous Leishmaniasis in an Immunocompetent Patient." Head and neck pathology vol. 15,3 (2021): 1069-1073. doi: https://doi.org/10.1007/s12105-020-01253-w
Botelho MCB, Ferreira LL, Fikaris S, Prado-Ribeiro AC, Soubhia AMP, Biasoli ER, Miyahara GI, Bernabé DG. Tongue Nodule as Primary Manifestation of American Cutaneous Leishmaniasis in an Immunocompetent Patient. Head Neck Pathol. 2021 Sep;15(3):1069-1073. doi: 10.1007/s12105-020-01253-w. Epub 2020 Dec 28. PMID: 33372239; PMCID: PMC8384968.
Copy Download .nbib Format: NLM
Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer.

Academic radiology

Fan X, Chatterjee A, Pittman JM, Yousuf A, Antic T, Karczmar GS, Oto A.
PMID: 34583866
Acad Radiol. 2021 Sep 25; doi: 10.1016/j.acra.2021.07.028. Epub 2021 Sep 25.

RATIONALE AND OBJECTIVES: To evaluate whether dynamic contrast enhanced (DCE) MRI with a split injection of 30% followed by 70% of a standard dose (30PSD and 70PSD) of gadoterate meglumine (DOTAREM) can improve diagnosis of prostate cancer (PCa).MATERIALS AND...

Cite
Fan X, Chatterjee A, Pittman JM, et al. Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer. Acad Radiol. 2021;doi: 10.1016/j.acra.2021.07.028.
Fan, X., Chatterjee, A., Pittman, J. M., Yousuf, A., Antic, T., Karczmar, G. S., & Oto, A. (2021). Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer. Academic radiology, . https://doi.org/10.1016/j.acra.2021.07.028
Fan, Xiaobing, et al. "Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer." Academic radiology vol. (2021). doi: https://doi.org/10.1016/j.acra.2021.07.028
Fan X, Chatterjee A, Pittman JM, Yousuf A, Antic T, Karczmar GS, Oto A. Effectiveness of Dynamic Contrast Enhanced MRI with a Split Dose of Gadoterate Meglumine for Detection of Prostate Cancer. Acad Radiol. 2021 Sep 25; doi: 10.1016/j.acra.2021.07.028. Epub 2021 Sep 25. PMID: 34583866.
Copy Download .nbib Format: NLM
Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs.

Water research

Tan C, Zhao H, Wang X, Yu H, Chong S, Xu Y, Du E, Chen M, Peng X, Su L.
PMID: 34952455
Water Res. 2021 Dec 19;210:117981. doi: 10.1016/j.watres.2021.117981. Epub 2021 Dec 19.

As a natural source of visible light and a type of renewable energy, solar energy is extensively used in the field of photochemistry. In this study, solar was employed to activate persulfate (PS) to degrade typical micropollutants. The removal...

Cite
Tan C, Zhao H, Wang X, et al. Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs. Water Res. 2021;210:117981doi: 10.1016/j.watres.2021.117981.
Tan, C., Zhao, H., Wang, X., Yu, H., Chong, S., Xu, Y., Du, E., Chen, M., Peng, X., & Su, L. (2021). Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs. Water research, 210117981. https://doi.org/10.1016/j.watres.2021.117981
Tan, Chaoqun, et al. "Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs." Water research vol. 210 (2021): 117981. doi: https://doi.org/10.1016/j.watres.2021.117981
Tan C, Zhao H, Wang X, Yu H, Chong S, Xu Y, Du E, Chen M, Peng X, Su L. Feasibility of micropollutants removal by solar-activated persulfate: Reactive oxygen species formation and influence on DBPs. Water Res. 2021 Dec 19;210:117981. doi: 10.1016/j.watres.2021.117981. Epub 2021 Dec 19. PMID: 34952455.
Copy Download .nbib Format: NLM
Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis.

Nanomedicine : nanotechnology, biology, and medicine

Khalid S, Salman S, Iqbal K, Rehman FU, Ullah I, Satoskar AR, Khan GM, Dar MJ.
PMID: 34748957
Nanomedicine. 2021 Nov 05;40:102490. doi: 10.1016/j.nano.2021.102490. Epub 2021 Nov 05.

The basic aim of the study was to develop and evaluate the triple drug loaded cationic nano-vesicles (cNVs), where miltefosine was used as a replacement of surfactant (apart from its anti-leishmanial role), in addition to meglumine antimoniate (MAM) and...

Cite
Khalid S, Salman S, Iqbal K, et al. Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis. Nanomedicine. 2021;40:102490doi: 10.1016/j.nano.2021.102490.
Khalid, S., Salman, S., Iqbal, K., Rehman, F. U., Ullah, I., Satoskar, A. R., Khan, G. M., & Dar, M. J. (2021). Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis. Nanomedicine : nanotechnology, biology, and medicine, 40102490. https://doi.org/10.1016/j.nano.2021.102490
Khalid, Sidra, et al. "Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis." Nanomedicine : nanotechnology, biology, and medicine vol. 40 (2021): 102490. doi: https://doi.org/10.1016/j.nano.2021.102490
Khalid S, Salman S, Iqbal K, Rehman FU, Ullah I, Satoskar AR, Khan GM, Dar MJ. Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis. Nanomedicine. 2021 Nov 05;40:102490. doi: 10.1016/j.nano.2021.102490. Epub 2021 Nov 05. PMID: 34748957.
Copy Download .nbib Format: NLM
Pediatric visceral leishmaniasis in Tartous, Syria.

Avicenna journal of medicine

Hamwi AO, Mohammad AA, Hamwi SO, Mohammad RA, Shahin KY.
PMID: 33437694
Avicenna J Med. 2020 Oct 13;10(4):223-226. doi: 10.4103/ajm.ajm_168_20. eCollection 2020.

BACKGROUND: Visceral leishmaniasis (VL) type in Syria is SUBJECTS AND METHODS: Hospital records of 19 children with VL were retrospectively reviewed. The period of the study was from June 2016 to July 2019.RESULTS: The median age of the patients...

Cite
Hamwi AO, Mohammad AA, Hamwi SO, et al. Pediatric visceral leishmaniasis in Tartous, Syria. Avicenna J Med. 2020;10(4):223-226doi: 10.4103/ajm.ajm_168_20.
Hamwi, A. O., Mohammad, A. A., Hamwi, S. O., Mohammad, R. A., & Shahin, K. Y. (2020). Pediatric visceral leishmaniasis in Tartous, Syria. Avicenna journal of medicine, 10(4), 223-226. https://doi.org/10.4103/ajm.ajm_168_20
Hamwi, Ali Othman, et al. "Pediatric visceral leishmaniasis in Tartous, Syria." Avicenna journal of medicine vol. 10,4 (2020): 223-226. doi: https://doi.org/10.4103/ajm.ajm_168_20
Hamwi AO, Mohammad AA, Hamwi SO, Mohammad RA, Shahin KY. Pediatric visceral leishmaniasis in Tartous, Syria. Avicenna J Med. 2020 Oct 13;10(4):223-226. doi: 10.4103/ajm.ajm_168_20. eCollection 2020. PMID: 33437694; PMCID: PMC7791284.
Copy Download .nbib Format: NLM
Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis.

Nanomedicine : nanotechnology, biology, and medicine

Khalid S, Salman S, Iqbal K, Rehman FU, Ullah I, Satoskar AR, Khan GM, Dar MJ.
PMID: 34748957
Nanomedicine. 2021 Nov 05;40:102490. doi: 10.1016/j.nano.2021.102490. Epub 2021 Nov 05.

The basic aim of the study was to develop and evaluate the triple drug loaded cationic nano-vesicles (cNVs), where miltefosine was used as a replacement of surfactant (apart from its anti-leishmanial role), in addition to meglumine antimoniate (MAM) and...

Cite
Khalid S, Salman S, Iqbal K, et al. Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis. Nanomedicine. 2021;40:102490doi: 10.1016/j.nano.2021.102490.
Khalid, S., Salman, S., Iqbal, K., Rehman, F. U., Ullah, I., Satoskar, A. R., Khan, G. M., & Dar, M. J. (2021). Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis. Nanomedicine : nanotechnology, biology, and medicine, 40102490. https://doi.org/10.1016/j.nano.2021.102490
Khalid, Sidra, et al. "Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis." Nanomedicine : nanotechnology, biology, and medicine vol. 40 (2021): 102490. doi: https://doi.org/10.1016/j.nano.2021.102490
Khalid S, Salman S, Iqbal K, Rehman FU, Ullah I, Satoskar AR, Khan GM, Dar MJ. Surfactant free synthesis of cationic nano-vesicles: A safe triple drug loaded vehicle for the topical treatment of cutaneous leishmaniasis. Nanomedicine. 2021 Nov 05;40:102490. doi: 10.1016/j.nano.2021.102490. Epub 2021 Nov 05. PMID: 34748957.
Copy Download .nbib Format: NLM
Medication control of flunixin in racing horses: Possible detection times using Monte Carlo simulations.

Equine veterinary journal

Kuroda T, Minamijima Y, Nomura M, Yamashita S, Yamada M, Nagata S, Mita H, Tamura N, Fukuda K, Kuwano A, Kusano K, Toutain PL, Sato F.
PMID: 34719043
Equine Vet J. 2021 Oct 30; doi: 10.1111/evj.13532. Epub 2021 Oct 30.

BACKGROUND: For medication control in several jurisdictions, withdrawal time is the period of refrain from racing after drug administration. It is set by adding a safety period to an experimental detection time. However, there are no reports of statistical...

Cite
Kuroda T, Minamijima Y, Nomura M, et al. Medication control of flunixin in racing horses: Possible detection times using Monte Carlo simulations. Equine Vet J. 2021;doi: 10.1111/evj.13532.
Kuroda, T., Minamijima, Y., Nomura, M., Yamashita, S., Yamada, M., Nagata, S., Mita, H., Tamura, N., Fukuda, K., Kuwano, A., Kusano, K., Toutain, P. L., & Sato, F. (2021). Medication control of flunixin in racing horses: Possible detection times using Monte Carlo simulations. Equine veterinary journal, . https://doi.org/10.1111/evj.13532
Kuroda, Taisuke, et al. "Medication control of flunixin in racing horses: Possible detection times using Monte Carlo simulations." Equine veterinary journal vol. (2021). doi: https://doi.org/10.1111/evj.13532
Kuroda T, Minamijima Y, Nomura M, Yamashita S, Yamada M, Nagata S, Mita H, Tamura N, Fukuda K, Kuwano A, Kusano K, Toutain PL, Sato F. Medication control of flunixin in racing horses: Possible detection times using Monte Carlo simulations. Equine Vet J. 2021 Oct 30; doi: 10.1111/evj.13532. Epub 2021 Oct 30. PMID: 34719043.
Copy Download .nbib Format: NLM
Clinical leishmaniosis in a domestic ferret (Mustela putorius furo) treated with miltefosine plus allopurinol: Serological and clinical follow-up.

Veterinary parasitology, regional studies and reports

Giner J, Villanueva-Saz S, Alcover MM, Riera C, Fisa R, Verde M, Fernández A, Yzuel A.
PMID: 34474800
Vet Parasitol Reg Stud Reports. 2021 Jul;25:100607. doi: 10.1016/j.vprsr.2021.100607. Epub 2021 Jul 10.

The published information on the treatment of mustelid leishmaniosis is extremely scarce because there are only two case reports available. In one case, a domestic ferret (Mustela putorius furo) was treated with a combination of meglumine antimoniate plus allopurinol...

Cite
Giner J, Villanueva-Saz S, Alcover MM, et al. Clinical leishmaniosis in a domestic ferret (Mustela putorius furo) treated with miltefosine plus allopurinol: Serological and clinical follow-up. Vet Parasitol Reg Stud Reports. 2021;25:100607doi: 10.1016/j.vprsr.2021.100607.
Giner, J., Villanueva-Saz, S., Alcover, M. M., Riera, C., Fisa, R., Verde, M., Fernández, A., & Yzuel, A. (2021). Clinical leishmaniosis in a domestic ferret (Mustela putorius furo) treated with miltefosine plus allopurinol: Serological and clinical follow-up. Veterinary parasitology, regional studies and reports, 25100607. https://doi.org/10.1016/j.vprsr.2021.100607
Giner, Jacobo, et al. "Clinical leishmaniosis in a domestic ferret (Mustela putorius furo) treated with miltefosine plus allopurinol: Serological and clinical follow-up." Veterinary parasitology, regional studies and reports vol. 25 (2021): 100607. doi: https://doi.org/10.1016/j.vprsr.2021.100607
Giner J, Villanueva-Saz S, Alcover MM, Riera C, Fisa R, Verde M, Fernández A, Yzuel A. Clinical leishmaniosis in a domestic ferret (Mustela putorius furo) treated with miltefosine plus allopurinol: Serological and clinical follow-up. Vet Parasitol Reg Stud Reports. 2021 Jul;25:100607. doi: 10.1016/j.vprsr.2021.100607. Epub 2021 Jul 10. PMID: 34474800.
Copy Download .nbib Format: NLM
Evaluation of the pharmacokinetics and efficacy of transdermal flunixin for pain mitigation following castration in goats.

Translational animal science

Graves MT, Schneider L, Cox S, Caldwell M, Krawczel P, Lee A, Lear A.
PMID: 33324963
Transl Anim Sci. 2020 Oct 30;4(4):txaa198. doi: 10.1093/tas/txaa198. eCollection 2020 Oct.

The mitigation of pain associated with common management procedures is a rising concern among veterinarians, producers and consumers. Nonsteroidal anti-inflammatory drugs are vital compounds for this purpose due to their cost, convenience, and efficacy. A transdermal formulation of flunixin...

Cite
Graves MT, Schneider L, Cox S, et al. Evaluation of the pharmacokinetics and efficacy of transdermal flunixin for pain mitigation following castration in goats. Transl Anim Sci. 2020;4(4):txaa198doi: 10.1093/tas/txaa198.
Graves, M. T., Schneider, L., Cox, S., Caldwell, M., Krawczel, P., Lee, A., & Lear, A. (2020). Evaluation of the pharmacokinetics and efficacy of transdermal flunixin for pain mitigation following castration in goats. Translational animal science, 4(4), txaa198. https://doi.org/10.1093/tas/txaa198
Graves, Meggan T, et al. "Evaluation of the pharmacokinetics and efficacy of transdermal flunixin for pain mitigation following castration in goats." Translational animal science vol. 4,4 (2020): txaa198. doi: https://doi.org/10.1093/tas/txaa198
Graves MT, Schneider L, Cox S, Caldwell M, Krawczel P, Lee A, Lear A. Evaluation of the pharmacokinetics and efficacy of transdermal flunixin for pain mitigation following castration in goats. Transl Anim Sci. 2020 Oct 30;4(4):txaa198. doi: 10.1093/tas/txaa198. eCollection 2020 Oct. PMID: 33324963; PMCID: PMC7724925.
Copy Download .nbib Format: NLM
Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents.

Radiology

Richter H, Bücker P, Martin LF, Dunker C, Fingerhut S, Xia A, Karol A, Sperling M, Karst U, Radbruch A, Jeibmann A.
PMID: 34546128
Radiology. 2021 Dec;301(3):637-642. doi: 10.1148/radiol.2021210553. Epub 2021 Sep 21.

Background There is an ongoing scientific debate about the degree and clinical importance of gadolinium deposition in the brain and other organs after administration of gadolinium-based contrast agents (GBCAs). While most published data focus on gadolinium deposition in the...

Cite
Richter H, Bücker P, Martin LF, et al. Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents. Radiology. 2021;301(3):637-642doi: 10.1148/radiol.2021210553.
Richter, H., Bücker, P., Martin, L. F., Dunker, C., Fingerhut, S., Xia, A., Karol, A., Sperling, M., Karst, U., Radbruch, A., & Jeibmann, A. (2021). Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents. Radiology, 301(3), 637-642. https://doi.org/10.1148/radiol.2021210553
Richter, Henning, et al. "Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents." Radiology vol. 301,3 (2021): 637-642. doi: https://doi.org/10.1148/radiol.2021210553
Richter H, Bücker P, Martin LF, Dunker C, Fingerhut S, Xia A, Karol A, Sperling M, Karst U, Radbruch A, Jeibmann A. Gadolinium Tissue Distribution in a Large-Animal Model after a Single Dose of Gadolinium-based Contrast Agents. Radiology. 2021 Dec;301(3):637-642. doi: 10.1148/radiol.2021210553. Epub 2021 Sep 21. PMID: 34546128.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 224 entries